Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT.
Ditschkowski, M
Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT. [electronic resource] - Bone marrow transplantation Aug 2009 - 265-6 p. digital
Publication Type: Case Reports; Letter
1476-5365
10.1038/bmt.2009.8 doi
Aged
Antineoplastic Agents--therapeutic use
Benzamides
Bone Marrow Transplantation
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--pathology
Leukemia, Myeloid, Acute--pathology
Male
Piperazines--therapeutic use
Pyrimidines--therapeutic use
Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT. [electronic resource] - Bone marrow transplantation Aug 2009 - 265-6 p. digital
Publication Type: Case Reports; Letter
1476-5365
10.1038/bmt.2009.8 doi
Aged
Antineoplastic Agents--therapeutic use
Benzamides
Bone Marrow Transplantation
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--pathology
Leukemia, Myeloid, Acute--pathology
Male
Piperazines--therapeutic use
Pyrimidines--therapeutic use